Cytokinetics outlined its long-term growth strategy at the Bernstein Insights Healthcare Leaders and Disruptors forum on September 23, 2026, projecting a pipeline expansion that would see the South San Francisco-based company reach five approved products across its cardiac portfolio by the end of the decade.
Executives framed MYQORZO, launched in the U.S. and Europe in 2024, as the foundation for what CEO Robert Blum described as an evolving franchise. The company has surpassed 700 prescribers, with dispensations rising from under 400 in Q1 2024 to roughly 1,500 in Q2 2024. New patient starts climbed from approximately 2,000 per quarter before launch to 2,500 in Q1 and 3,000 in Q2, according to the company.
MYQORZO captured more than 40% of all new cardiac myosin inhibitor prescriptions in its first year, and Cytokinetics targets a 50% share by year-end. The addressable market remains substantial: an estimated 110,000 to 120,000 patients in the U.S. have diagnosed obstructive hypertrophic cardiomyopathy (HCM), though only 20,000 to 25,000 are currently receiving therapy, while approximately 50,000 patients have non-obstructive HCM.
The company’s Vision 2030 framework calls for two approved therapies across three indications, ten new molecular entities in development, operations in more than 15 countries, and reaching at least 100,000 patients through clinical trials and commercialization.
Beyond MYQORZO, Cytokinetics highlighted two late-stage programs. Omecamtiv mecarbil, a cardiac myosin activator that does not perturb calcium cycling or increase oxygen demand, is expected to deliver top-line COMET study data in 2028. Dan Jacoby, vice president of clinical research, noted the drug’s distinct mechanism increases heart contractility without causing cellular injury.
Ulacamten, another in-development candidate, is completing AMBER study enrollment expected in 2024, with initial cohort results due in 2027.
Isaac Ciechanover, executive vice president of corporate development and chief business officer, said the company’s trajectory traces back to foundational research by early scientist Fady I. Malik, whose work underpins every major therapeutic in the cardiac myosin inhibitor space.
On September 23, Cytokinetics shares traded at $67.33, down 0.39%, with a market capitalization of $9.3 billion. Trailing twelve-month revenue was $67.67 million, and Wall Street projects 67% revenue growth for fiscal 2026. Analyst price targets range from $85 to $146.
